BioMarin (BMRN) Posts Q4 Earnings Beat, Upbeat Voxzogo Sales [Yahoo! Finance]
BioMarin Pharmaceutical Inc. (BMRN)
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.biomarin.com
Company Research
Source: Yahoo! Finance
The reported earnings rose 48% year over year, driven by an increase in revenues that also offset the impact of rising R&D expenses. Total revenues were $646.2 million in the reported quarter, up 20% year over year. The global uptake of Voxzogo and higher Vimizim revenues drove the upside. The top line beat the Zacks Consensus Estimate of $636.7 million. Quarter in Detail Product revenues (including Aldurazyme) totaled $633.1 million, up 20% year over year. The same from BioMarin's marketed brands (excluding Aldurazyme) increased 21% year over year to $590.4 million on higher revenues from Voxzogo. This offset lower sales from Kuvan. Royalty and other revenues totaled $13.1 million, up 8% year over year. Voxzogo, approved for achondroplasia, generated sales of $145.7 million, up 118% year over year and 18% quarter over quarter. Higher sales of Voxzogo were fuelled by the U.S. label expansion to younger age groups (under five years). This label expansion was received last year
Show less
Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
News
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Morgan Stanley from $115.00 to $112.00. They now have an "overweight" rating on the stock.MarketBeat
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $91.00 to $89.00. They now have a "hold" rating on the stock.MarketBeat
- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Global Cell and Gene Therapies in Hemophilia A & B Analysis Report 2024: Market to Reach $2.2 Billion by 2029 - Major Players Are Expected To Intensify Competition [Yahoo! Finance]Yahoo! Finance
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Citigroup Inc. from $94.00 to $91.00. They now have a "neutral" rating on the stock.MarketBeat
BMRN
Earnings
- 4/24/24 - Beat
BMRN
Sec Filings
- 4/26/24 - Form 10-Q
- 4/24/24 - Form 8-K
- 4/23/24 - Form 8-K
- BMRN's page on the SEC website